Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients.

Autor: Padillo-Ruiz J; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Suarez G; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Pereira S; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Calero-Castro FJ; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Tinoco J; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Marin L; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Bernal C; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Cepeda-Franco C; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Alamo JM; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Almoguera F; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Macher HC; Department of Molecular Biochemistry, University Hospital Virgen del Rocío, 41013 Seville, Spain., Villanueva P; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., García-Fernandez FJ; Department of Gastroenterology, University Hospital Virgen del Rocío, 41013 Seville, Spain., Gallego I; Department of Oncology, University Hospital Virgen del Rocío, 41013 Seville, Spain., Romero M; Department of Gastroenterology, University Hospital Virgen del Rocío, 41013 Seville, Spain., Gomez-Bravo MA; Instituto de Biomedicina de Sevilla, University Hospital Virgen del Rocío, 41013 Seville, Spain., Denninghoff V; Molecular-Clinical Lab, University of Buenos Aires (UBA)-National Council for Scientific and Technical Research (CONICET), Buenos Aires C1122AAH, Argentina., Serrano MJ; Oncology Unit, Centre for Genomics and Oncological Research-GENYO, Pfizer, University of Granada, Andalusian Regional Government, 18016 Granada, Spain.; Integral Oncology Division, Instituto Biosantario Granada (iBS-Granada), Virgen de las Nieves University Hospital, 18012 Granada, Spain.; Department of Pathological Anatomy, Faculty of Medicine, University of Granada, 18071 Granada, Spain.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Dec 07; Vol. 13 (24). Date of Electronic Publication: 2021 Dec 07.
DOI: 10.3390/cancers13246153
Abstrakt: Background: Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal blood (PV).
Methods: In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by Epi-fluorescence and confocal microscopy.
Results: CTC and the clusters were detected both in PV and CVC. In both samples, the CTC number per cluster was higher in patients with grade three or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated. Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than 185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant correlations were not observed in CVC analyses.
Conclusions: CTC presence in PV could be an important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could be used as a diagnostic biomarker for pancreatic cancer.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje